Filing Flows › Agilent Technologies (A) › Q3 FY26 › vs Q3 FY25
Agilent Technologies (A) Q3 FY26 vs Q3 FY25 (year over year)
Agilent Technologies's revenue rose $140M (+8%) from $1.7B in Q3 FY25 to $1.9B in Q3 FY26. The biggest changes: Life Sciences and Diagnostics Markets +$76.0M (+11%); Agilent CrossLab +$42.0M (+6%); Applied Markets +$22.0M (+7%). Operating margin 23.6% against 20.7% (+2.9 pts).
Agilent Technologies, Q3 FY26: revenue $1.9B (+8% year over year), operating margin 23.6%, net earnings $362M, operating cash flow $519M. The chart draws each line against Q3 FY25, the increases inside each band.
Margins
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Operating margin | 23.6% | 20.7% | +2.9 pts |
| Net margin | 19.3% | 19.3% | -0.1 pts |
| Free cash flow margin | 23.4% | 14.9% | +8.5 pts |
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Agilent CrossLab | $786M | $744M | $42.0M | +6% |
| Life Sciences and Diagnostics Markets | $746M | $670M | $76.0M | +11% |
| Applied Markets | $346M | $324M | $22.0M | +7% |
| Revenue | $1.9B | $1.7B | $140M | +8% |
| Operating profit | $444M | $360M | $84.0M | +23% |
| Costs & expenses | $1.4B | $1.4B | $56.0M | +4% |
| Pre-tax earnings | $444M | $366M | $78.0M | +21% |
| Cost of revenue | $836M | $850M | −$14.0M | -2% |
| Research & development | $123M | $111M | $12.0M | +11% |
| SG&A | $475M | $417M | $58.0M | +14% |
| Net earnings | $362M | $336M | $26.0M | +8% |
| Income tax | $82.0M | $30.0M | $52.0M | +173% |
| Depreciation & amortization | $66.0M | $72.0M | −$6.0M | -8% |
| Share-based compensation | $32.0M | $32.0M | $0 | 0% |
| Working capital & other | $59.0M | −$78.0M | $137M | — |
| Operating cash flow | $519M | $362M | $157M | +43% |
| Free cash flow (OCF − capex) | $439M | $259M | $180M | +69% |
| Capital expenditures | $80.0M | $103M | −$23.0M | -22% |
Questions
How much did Agilent Technologies's revenue grow year over year in Q3 FY26?
Agilent Technologies's revenue rose $140M (+8%) from $1.7B in Q3 FY25 to $1.9B in Q3 FY26.
What drove Agilent Technologies's revenue change in Q3 FY26?
Life Sciences and Diagnostics Markets +$76.0M (+11%); Agilent CrossLab +$42.0M (+6%); Applied Markets +$22.0M (+7%).